James Mulay Sells Shares of CG Oncology, Inc.

On June 15, 2026, James Mulay sold 1,964 shares of CG Oncology, Inc. (NasdaqGS: CGON) in a planned transaction. The shares were sold at an average price of $60.12, amounting to a total value of $118,075.68. CG Oncology's shares were trading at $59.55 at the time of the transaction.

Insider Buying and Selling at CG Oncology, Inc.

James Mulay's sale of 1,964 shares on June 15 was part of a planned transaction. Other recent insider activities included Leonard Post selling 1,000 shares on June 4, and Christina Rossi and Victor Edward Jr. each purchasing 9,354 shares on the same date.

Other Institutional Activity in CG Oncology, Inc.

RTW Investments, LP significantly increased its holdings in CG Oncology, adding 4,972,681 shares to end with 6,984,808 shares valued at approximately $472.7 million. T. Rowe Price Investment Management, Inc. also boosted its position, adding 6,297,797 shares for a total of 6,720,389 shares worth $454.8 million. Conversely, Wellington Management Group LLP reduced its stake by 628,558 shares, holding 5,371,232 shares valued at $363.5 million.

CG Oncology, Inc. Stock Down 18.9%

Shares of CG Oncology, Inc. (NasdaqGS: CGON) traded around $59.55. The company has a market capitalization of $5.25 billion and a beta of 0.308, indicating lower volatility compared to the market. The stock's 52-week range is between $23.65 and $75.50, with a 50-day moving average of $64.93 and a 200-day moving average of $51.37. The company is not currently profitable, reflected in its negative forward P/E ratio of -21.43.

Recent Earnings

CG Oncology reported revenue of $5.07 million with a growth rate of 19.8%. Despite the revenue increase, the company posted a net margin of 0.0% and a return on equity of -20.79%. The next earnings report is expected on August 7, 2026.

Analysts Set New Price Targets

On May 14, 2026, Truist Securities reiterated its 'buy' rating for CG Oncology with a price target of $82. JP Morgan and RBC Capital also maintained 'buy' ratings on May 11, with targets of $96 and $81, respectively. The consensus target price among analysts is $90.29, based on 14 opinions.

About CG Oncology, Inc.

CG Oncology, Inc. is a biopharmaceutical company based in Dallas, Texas. It focuses on developing and commercializing treatments for bladder cancer, particularly through its product candidate, cretostimogene grenadenorepvec. The company is engaged in multiple clinical trials to evaluate the safety and efficacy of its oncolytic immunotherapy, including several phase 3 trials. Founded in 2010 and led by CEO Mr. Arthur Kuan, CG Oncology aims to address unmet needs in cancer treatment.

Bottom Line

James Mulay's recent sale of CG Oncology shares was part of a planned transaction, highlighting ongoing insider activity within the company. Investors and analysts continue to keep a close watch on CG Oncology due to its ongoing clinical trials and potential market impact. As always, it's important to remember that insider transactions are reported after they occur and may not reflect current positions.